-
Front Oncol: Comparison of survival between local and systemic treatments for brain metastases from non-small cell lung cancer as the first treatment
Time of Update: 2021-12-04
diagnosis Factors related to prognosis Factors related to prognosis and factors related to prognosisFor 111 patients with symptomatic brain metastases, univariate analysis showed that the factors leading to prolonged survival were as follows: less than 65 years of age, more than 3 cycles of chemotherapy, SRS and TKI drug treatment .
-
Odivo combined with chemotherapy and neoadjuvant therapy can significantly improve event-free survival in non-small cell lung cancer
Time of Update: 2021-12-03
Princeton, NJ, USA, November 9, 2021/PRNewswire/ - Bristol-Myers Squibb (NYSE: BMY) announced that the Phase III clinical study CheckMate-816 can be cut from Phase IB to Phase IIIA unless minor The primary research endpoint of improving event-free survival (EFS) in patients with cell lung cancer (NSCLC) .
-
CheckMate-816 Phase III data released: neoadjuvant therapy for patients with non-small cell lung
Time of Update: 2021-12-03
2021 Nian 11 Yue 8 days, Bristol-Myers Squibb (NYSE: BMY ) announced that, BMY III clinical study of CheckMate-816 study in the IB period to IIIA of resectable non-small cell lung cancer ( NSCLC patients) achieved in improving The primary research endpoint of event-free survival ( EFS ) .
-
Front Oncol: The impact of blood glucose control on the survival of advanced non-small cell lung cancer (NSCLC) patients with diabetes
Time of Update: 2021-12-02
Recently, Frontiers in Oncology published the results of a study from the team of Shanghai Chest Hospital of Shanghai Jiaotong University, aiming to assess the prognosis of patients with advanced non-small cell lung cancer (NSCLC) with diabetes, and to assess whether the best blood sugar control is Can improve overall survival (OS) .
-
in the treatment of patients with non-small cell lung cancer in Singapore
Time of Update: 2021-11-15
The Phase Ib/II trial will evaluate the efficacy of this new combination therapy in advanced non-small cell lung cancer (NSCLC) patients who have progressed after previous treatment .
-
Hengrui Pharmaceuticals PD-L1 in the treatment of extensive-stage small cell lung cancer phase III clinical study reached the primary endpoint
Time of Update: 2021-11-15
Recently, Hengrui Medicine's new class 1 drug PD-L1 monoclonal antibody SHR-1316 (Adbelizumab injection) combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer is a randomized, double-blind, placebo-controlled, multi-center phase III The main research endpoint of the clinical study (SHR-1316-III-301) reached the pre-specified superiority standard .
-
Kangfang Bio-PD-1/VEGF Double Antibody Approved for Phase II Clinical Treatment of Non-Small Cell Lung Cancer
Time of Update: 2021-11-14
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 2, Kangfang Biological announced that the new tumor immunotherapy drug AK112 (PD-1/VEGF bispecific antibody) was approved by CDE, and the development of single-drug or combined chemotherapy neoadjuvant/adjuvant therapy can cut non-small cell lung cancer (NSCLC).
-
with advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) after chemotherapy
Time of Update: 2021-11-13
Subgroup analysisSubgroup analysisThe most common TEAEs of any grade in patients in the pemetrexed maintenance group ( incidence ≥20% during the entire treatment cycle ) were nausea, fatigue, vomiting, anemia, neutropenia, constipation, decreased appetite, fatigue, Peripheral edema and insomnia .
-
Case Analysis|Clinical Application of First-line Immunization Combined with Chemotherapy for Extensive Stage Small Cell Lung Cancer
Time of Update: 2021-11-13
The progress of first-line immunotherapy for extensive-stage small cell lung cancer is summarized as follows: 1PD-L1 inhibitor combined with chemotherapy IMpower133 study [1] is a randomized, double-blind, multi-center phase III clinical study, including 403 newly-treated ED-SCLC patients , One group received 4 cycles of atezizumab + EP regimen induction, and then followed by atilizumab maintenance treatment; the other group was treated with EP + placebo, followed by placebo maintenance treatment .
-
JCO: The prognosis of stage 3 gefitinib vs. cisplatin + vinorelbine for adjuvant treatment of non-small cell lung cancer after surgical resection
Time of Update: 2021-11-13
Although cisplatin-based adjuvant chemotherapy is the standard treatment for stage II and stage III non-small cell lung cancer ( NSCLC ) that are completely resected by surgery , the survival prognosis of patients is not satisfactory .
-
(bevacizumab injection) and chemotherapy for the treatment of EGFR-mutant non-squamous non-small cell lung
Time of Update: 2021-11-05
San Francisco and Suzhou, China October 18, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the
-
Can targeted/immunotherapy become the "key" to the survival of stage III non-small cell lung cancer?
Time of Update: 2021-11-04
■ Neoadjuvant treatment plan of atilizumab combined with chemotherapy This open-label, multi-center, single-arm, phase II study included patients ≥18 years of age, stage IB-IIIA resectable NSCLC, and ECOG score of 0-1 Patient .
-
advanced non-small cell lung cancer in China has been accepted by the China National Medical Products Administration
Time of Update: 2021-11-04
Suzhou, China, October 20, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, It was announced today that the clinical trial application (IND) of lorlatinib (lorlatinib, formerly known as loratinib) for ROS1-positive advanced non-small cell lung cancer (NSCLC) has been accepted by the National Medical Products Administration (NMPA) of China .
-
Sintilimab Combination Therapy Achieves Primary Endpoint in Phase 3 Clinical Treatment for Non-Small Cell Lung Cancer
Time of Update: 2021-11-04
Reference materials:[1] Innovent announces that daboshu (sintilimab injection) combined with dayoto (bevacizumab injection) and chemotherapy are used to treat non-squamous non-squamous EGFR mutations that have failed EGFR-TKI treatment The Phase III clinical study of cell lung cancer reached the primary research endpoint.
-
Cancer Commun: Clinical characteristics and prognosis analysis of Chinese KRAS mutant non-small cell lung cancer patients after chemotherapy
Time of Update: 2021-11-02
Clinical studies have shown that white patients with non-small cell lung cancer with KRAS mutations have a poor prognosis after first-line chemotherapy .
Clinical studies have shown that white patients with non-small cell lung cancer with KRAS mutations have a poor prognosis after first-line chemotherapy .